CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--Alkermes, Inc.
(Nasdaq: ALKS) announced today that its corporate presentation will be
webcast live by The Biotechnology Industry Organization (BIO) on
Monday, February 12, 2007 at 11:45 a.m. EST. The presentation will be
webcast from The Waldorf Astoria Hotel in New York and may be accessed
under the investor relation's tab at www.alkermes.com. The
presentation will be archived for 14 days.
Alkermes, Inc. is a biotechnology company that develops innovative
medicines designed to yield better therapeutic outcomes and improve
the lives of patients with serious disease. Alkermes currently has two
commercial products: RISPERDAL® CONSTA® ((risperidone) long-acting
injection), the first and only long-acting atypical antipsychotic
medication approved for use in schizophrenia, and marketed worldwide
by Janssen-Cilag (Janssen), a wholly owned division of Johnson &
Johnson; and VIVITROL® (naltrexone for extended-release injectable
suspension) the first and only once-monthly injectable medication
approved for the treatment of alcohol dependence and marketed in the
U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes
extended-release injectable, pulmonary, and oral products for the
treatment of prevalent, chronic diseases such as central nervous
system disorders, addiction and diabetes. Alkermes' headquarters are
in Cambridge, Massachusetts, and it operates research and
manufacturing facilities in Massachusetts and Ohio.
CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications
SOURCE: Alkermes, Inc.